title: Bioreductive drugs and the selective induction of tumour hypoxia.
abstract: In this work tumour hypoxia is induced by physically occluding the tumour vascular supply by clamping, or by giving mice 5 mg kg-1 hydralazine. These methods have previously been shown to increase the radiobiological hypoxic fraction in tumours close to 100%. Their effectiveness in potentiating the bioreductive toxicity of: misonidazole (800 mg kg-1), RSU1069 (80 mg kg-1), mitomycin C (5 mg kg-1) and SR4233 (50 mg kg-1) is assessed in the RIF-1 and KHT tumours using regrowth delay as an assay. Clamping alone for 120 min gives little or no response, but when RSU1069 is administered 15 min before clamping, large growth delays result. RIF-1 tumours clamped for 90 or 120 min with RSU1069 give cure rates of 12.5% and 37.5% respectively. Less effect with clamping is seen for the other bioreductive agents. The effect of hydralazine with RSU1069 although significant in the RIF-1 tumour, is modest compared to that for clamping. Small enhancements of toxicity are seen with hydralazine in combination with misonidazole in the RIF-1 tumour and mitomycin C in both tumours. The varying effectiveness of these treatments is attributed to several factors which include the level and duration of hypoxia, concentration and contact time of the bioreductive drugs, the microenvironment of the tumour and the nature of the reductive metabolic pathways available in the different tumour cell types.
authors.affiliation: MRC Radiobiology Unit, Chilton, Didcot, Oxfordshire, UK.
authors.forename: J C
authors.initials: JC
authors.lastname: Bremner
authors.forename: I J
authors.initials: IJ
authors.lastname: Stratford
authors.forename: J
authors.initials: J
authors.lastname: Bowler
authors.forename: G E
authors.initials: GE
authors.lastname: Adams
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015687:Cell Hypoxia / Q000187:drug effects*; D003250:Constriction; D006830:Hydralazine; D051379:Mice; D008809:Mice, Inbred C3H; D008920:Misonidazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D016685:Mitomycin; D008937:Mitomycins / Q000627:therapeutic use; D011838:Radiation-Sensitizing Agents; D012513:Sarcoma, Experimental / Q000098:blood supply / Q000188:drug therapy / Q000473:pathology*; D000077704:Tirapazamine; D014227:Triazines / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D008937:Mitomycins; D011838:Radiation-Sensitizing Agents; D014227:Triazines; D000077704:Tirapazamine; D006830:Hydralazine; D016685:Mitomycin; C041712:1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol; D008920:Misonidazole